Literature DB >> 7702404

Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730.

P Hilliquin1, J Natour, J Aissa, P Guinot, S Laoussadi, J Benveniste, C J Menkes, B Arnoux.   

Abstract

OBJECTIVE: To evaluate the role of platelet activating factor (PAF) in the early stage of arthritis.
METHODS: Arthritis was induced in rabbits by weekly intra-articular injections of carrageenan. A PAF receptor antagonist, BN 50730, was used as a preventive or curative agent.
RESULTS: BN 50730 was able partially to prevent the development of arthritis, and was also active on established arthritis. The joint arthritis scores of BN treated animals were significantly lower than those of the non-treated animals. The blood concentrations of PAF, PAF bound to lipoproteins (lipo-PAF), and its precursor, lyso-PAF, were not correlated with clinical variations.
CONCLUSIONS: The present data demonstrate a therapeutic action of a PAF antagonist in experimental arthritis and suggest a critical role for PAF during the early stage of arthritis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7702404      PMCID: PMC1005539          DOI: 10.1136/ard.54.2.140

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.

Authors:  A Dulioust; P Hilliquin; C J Menkes; J Benveniste; B Arnoux
Journal:  Scand J Rheumatol       Date:  1992       Impact factor: 3.641

2.  Human neutrophil-derived platelet activating factor.

Authors:  G Z Lotner; J M Lynch; S J Betz; P M Henson
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

3.  Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets.

Authors:  H Chap; G Mauco; M F Simon; J Benveniste; L Douste-Blazy
Journal:  Nature       Date:  1981-01-22       Impact factor: 49.962

4.  Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.

Authors:  M C Dyson; J A Bellan; R K Minkes; R C Beckerman; M J Wegmann; P Braquet; D B McNamara; P J Kadowitz
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

5.  [Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine].

Authors:  J Benveniste; M Tencé; P Varenne; J Bidault; C Boullet; J Polonsky
Journal:  C R Seances Acad Sci D       Date:  1979-11-26

6.  Presence of paf-acether in rheumatic diseases.

Authors:  P Hilliquin; C J Menkes; S Laoussadi; J Benveniste; B Arnoux
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

7.  Platelet-activating factor inhibits proteoglycan synthesis and enhances neutrophil-mediated proteoglycan degradation in cartilage explants.

Authors:  I C Kowanko; E J Bates; A Ferrante
Journal:  Arthritis Rheum       Date:  1992-08

8.  Antigenic release of paf-acether and beta-glucuronidase from alveolar macrophages of asthmatics.

Authors:  B Arnoux; M Joseph; M H Simoes; A B Tonnel; P Duroux; A Capron; J Benveniste
Journal:  Bull Eur Physiopathol Respir       Date:  1987 Mar-Apr

9.  Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021.

Authors:  H Lachachi; M Plantavid; M F Simon; H Chap; P Braquet; L Douste-Blazy
Journal:  Biochem Biophys Res Commun       Date:  1985-10-30       Impact factor: 3.575

10.  Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor.

Authors:  J Benveniste; P M Henson; C G Cochrane
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  1 in total

1.  Platelet activating factor (PAF) antagonists on cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC).

Authors:  J H Wang; G Y Sun
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.